Amgen reports nine Phase 3 MariTide trials and one remaining obesity asset

Amgen's second-quarter report, released August 4, 2026, put nine global Phase 3 trials of its obesity drug MariTide in the field and confirmed the company has dropped an earlier-stage obesity candidate, leaving MariTide as its only obesity asset in development ^[1][2].

The nine Phase 3 studies cover obesity, type 2 diabetes, cardiovascular disease, heart failure and obstructive sleep apnea, according to the quarterly report ^[1]. Three more Phase 3 trials in type 2 diabetes are scheduled to start during 2026, and a Phase 2b study measuring liver fat is enrolling ^[1]. The two lead obesity trials, MARITIME-1 and MARITIME-2, carry primary completion dates of January 2027 ^[1]. ObesityIntel's pipeline tracker lists the Phase 3 MARITIME program as running 72 weeks ^[2].

What MariTide has shown so far comes from Phase 2. The tracker lists weight loss of up to about 20% at 52 weeks on the efficacy estimand, with 12.3% to 16.2% under the treatment-policy estimand, which counts everyone who entered the study ^[2]. MariTide is dosed monthly, which the tracker describes as a potential convenience edge, and is listed as a GLP-1/GIP drug ^[2].

For scale, the same tracker lists Eli Lilly's retatrutide at 28.3% weight loss at 80 weeks in the TRIUMPH-1 trial and Novo Nordisk's CagriSema at about 22.7% ^[2]. Those are separate trials with different lengths and patient groups; head-to-head comparisons of these drugs have not been reported ^[2].

On the finances, Amgen reported second-quarter total revenues up 10% to $10.1 billion and product sales up 9%, driven by volume ^[1]. GAAP earnings per share rose 65%, from $2.65 to $4.37, and non-GAAP earnings per share rose 4%, from $6.02 to $6.29 ^[1]. Free cash flow was $3.5 billion, up from $1.9 billion a year earlier ^[1]. Twenty-two products grew sales at double-digit rates, and 17 are annualizing above $1 billion based on second-quarter sales ^[1].

"Our results demonstrate strong performance across our business," chairman and chief executive Robert A. Bradway said, adding that Amgen is advancing "the next wave of pipeline molecules through Phase 3" ^[1].

The discontinued candidate is described differently in the two accounts. The quarterly disclosure identified it as AMG 513 ^[1], while ObesityIntel calls it an undisclosed early-stage obesity candidate discontinued on August 4, 2026 ^[2], and its pipeline tracker separately still lists AMG 513 as an Amgen Phase 1 asset ^[2]. Either way, the tracker's read is that Amgen's obesity bet now rests on MariTide alone ^[2].

The backdrop is a market where Lilly reported second-quarter revenue of $23.0 billion, up 48%, with Mounjaro at $9.9 billion and US Zepbound at $4.9 billion; Foundayo, the oral GLP-1 orforglipron, brought in $98 million in its first full quarter, and Lilly raised full-year revenue guidance to $85 billion to $87 billion ^[2]. Novo Nordisk, which reported a day earlier, posted adjusted operating profit of 33.4 billion Danish kroner, up 11% ^[2].

Why it matters for patients

MariTide is not approved and is not available by prescription; it can only be obtained by joining a trial, and no filing or approval date has been disclosed ^[1][2]. With the two lead obesity trials listing primary completion dates of January 2027 ^[1], any regulatory decision would come after that, and the heart-failure, sleep apnea, cardiovascular, liver-fat and diabetes studies have not reported results ^[1].

Patients deciding on treatment today have approved options. The tracker lists semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), oral semaglutide (the Wegovy pill) and orforglipron (Foundayo), approved in April 2026 ^[2]. If MariTide succeeds, it would add a monthly-dosed alternative to that list ^[2].

The concentration of Amgen's pipeline matters as well. With the early-stage candidate gone, the tracker counts one Amgen obesity asset ^[2]. If MariTide fails in Phase 3, one fewer competitor would be pushing into a market now dominated by Lilly and Novo Nordisk ^[2].

What happens next

• Three Phase 3 type 2 diabetes trials are set to begin in 2026, and the Phase 2b liver-fat study is enrolling ^[1].
• MARITIME-1 and MARITIME-2 list primary completion dates of January 2027 ^[1].
• For context, Novo Nordisk's CagriSema faces a US FDA decision in the second half of 2026, and Lilly has guided to a filing for retatrutide in the first quarter of 2027 ^[2].
• Amgen has not disclosed when it plans to file MariTide for approval ^[1].